Repeated Low-Level Red Light Therapy Exhibits Clinical Significance As Short-Term Alternative For Childhood Myopia Control: Study
- byDoctor News Daily Team
- 02 July, 2025
- 0 Comments
- 0 Mins
 
                            
                                    Egypt: Repeated Low-Level Red Light (RLRL) treatment for childhood myopia treatment demonstrated significant benefits over single-vision spectacles, recent research published in BMC Ophthalmology has revealed.
The systematic review and meta-analysis showed that RLRL treatment demonstrated significant benefits in terms of reducing axial length (AL), positively impacting subfoveal choroidal thickness (SFCT), and improving spherical equivalent refraction (SER) over a 3, 6, and 12-month follow-up.
"Repeated Low-Level Red Light exhibited clinical significance as a short-term alternative for myopia control with good user acceptability and no documented functional or structural damage," the researchers wrote. However, the long-term effects of RLRL treatment and the rebound effect after cessation require further investigations."
According to the researchers, this is the first systematic review and meta-analysis investigating only randomized controlled trials (RCTs) evidence supporting the efficacy of 650 nm RLRL for myopia control in the short term of 3, 6, and 12 months follow-up.
Myopia is the most prevalent form of refractive error that has a major adverse effect on visual function and causes blurring of vision. High myopia is linked to a significant risk of disorders that permanently impair vision, such as glaucoma, myopic maculopathy, retinal detachment, and staphyloma. As a result, myopia is a significant public health issue, and a strategy is urgently needed to stop its progression.
Mohamed Ashraf Youssef, Faculty of Medicine, Beni Suef University, Beni Suef City, Beni Suef, Egypt, and colleagues sought to determine if Repeated Low-Level Red Light treatment is beneficial in treating childhood myopia in terms of spherical equivalent refraction, axial length, and subfoveal choroidal thickness.
For this purpose, the researchers performed a systematic review of RLRL for myopia treatment in children compared to single vision spectacles (SVS). They employed a search strategy with keywords myopia and low-level light therapy, then they searched for online databases. The mean differences (MD) were used to evaluate the treatment effects.
The meta-analysis included five RCTs comprising 833 patients, 407 in the treatment group and 426 in the control group.
Based on the review, the researchers reported the following findings:
At a 3-month follow-up period, pooled studies show a statistical difference in AL between the RLRL and SVS group (MD = -0.16, SER (MD = 0.33), and SFCT (MD = 43.65).
At a 6 month follow-up period, pooled studies show a statistical difference in AL between the RLRL and SVS group (MD = -0.21), SER (MD = 0.46), and SFCT (MD = 25.07).
At a 12-month follow-up period, pooled studies show a statistical difference in AL between RLRL and SVS group (MD = -0.31) and SER (MD = 0.63).
In conclusion, the findings showed the clinical significance of RLRL for myopia control concerning SER, AL, and SFCT. It slowed down and reversed the myopia progression in a large proportion of children. RLRL therapy is an effective new alternative treatment for myopia control. However, there is a need to investigate the effect of long-term RLRL treatment and the rebound effect after cessation.
Reference:
Youssef, M.A., Shehata, A.R., Adly, A.M. et al. Efficacy of Repeated Low-Level Red Light (RLRL) therapy on myopia outcomes in children: a systematic review and meta-analysis. BMC Ophthalmol 24, 78 (2024). https://doi.org/10.1186/s12886-024-03337-5
                                
    Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
    The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
    Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
    If you come across any inconsistencies, please reach out to us at 
    admin@doctornewsdaily.com.
    We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
    By using this website, you agree to our 
    Terms of Use, 
    Privacy Policy, and 
    Advertisement Policy.
    For further details, please review our 
    Full Disclaimer.
Recent News
Merck Keytruda wins European Commission nod for lo...
- 30 October, 2025
UP NEET 2025 round 3 allotment results postponed
- 30 October, 2025
Achin Gupta to succeed Umang Vohra as Cipla MD, GC...
- 30 October, 2025
Mumbai shocker: KEM Hospital doctor stabbed by col...
- 30 October, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
 
                     
                    
0 Comments
Post a comment
No comments yet. Be the first to comment!